Prime Medicine, Inc. Payments of Stock Issuance Costs
Prime Medicine, Inc. (PRME) reported Payments of Stock Issuance Costs of $10.10 million for the 1-month period ending 2024-02-29, per its 10-K filed 2025-02-28.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2025-02-28
- Prime Medicine, Inc. payments of stock issuance costs for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Prime Medicine, Inc. payments of stock issuance costs for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Prime Medicine, Inc. payments of stock issuance costs for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Prime Medicine, Inc. payments of stock issuance costs for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Prime Medicine, Inc. payments of stock issuance costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Prime Medicine, Inc. payments of stock issuance costs for fiscal 2022 was $4.04M, a 272.19% increase from fiscal 2021.
- Prime Medicine, Inc. payments of stock issuance costs for fiscal 2021 was $1.09M, a 5330.00% increase from fiscal 2020.
- Prime Medicine, Inc. payments of stock issuance costs for fiscal 2020 was $20.00K.
| Period end | Payments of Stock Issuance Costs 1 month | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2024-02-29 | $10.10M 10-K · filed 2025-02-28 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $0.00 derived: sum of 2 quarters · filed 2024-03-01 | $0.00 derived: sum of 3 quarters · filed 2024-03-01 | $0.00 10-K · filed 2024-03-01 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 derived: sum of 2 quarters · filed 2023-11-03 | $0.00 10-Q · filed 2023-11-03 | $1.40M derived: sum of 4 quarters · filed 2024-03-01 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | $1.40M derived: sum of 3 quarters · filed 2024-03-01 | $2.15M derived: sum of 4 quarters · filed 2024-03-01 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $1.40M derived: sum of 2 quarters · filed 2024-03-01 | $2.15M derived: sum of 3 quarters · filed 2024-03-01 | $2.77M derived: sum of 4 quarters · filed 2024-03-01 | |
| 2022-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $2.15M derived: sum of 2 quarters · filed 2024-03-01 | $2.77M derived: sum of 3 quarters · filed 2024-03-01 | $4.04M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $746.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $1.37M derived: sum of 2 quarters · filed 2023-11-03 | $2.64M 10-Q · filed 2023-11-03 | $3.73M derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | $624.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.90M 10-Q · filed 2023-08-07 | $2.98M derived: sum of 3 quarters · filed 2023-08-07 | ||
| 2022-03-31 | $1.27M 10-Q · filed 2023-05-11 | $2.36M derived: sum of 2 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.09M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | ||||
| 2020-12-31 | $20.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |